Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amsacrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2B known ✓ | Q02880 | 5/20 | 1.00 |
| ▸ | TOP2A known ✓ | P11388 | 4/20 | 1.00 |
| ▸ | KDM1A | O60341 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | CASP1 | P29466 | 2/20 | 1.00 |
| ▸ | CASP7 | P55210 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | TOP1 | P11387 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amsacrine SCHEMBL29360354 | 1.00 | TOP2B (1.00) | TOP2BTOP2AKDM1ACYP1A2CYP2D6 | |
| Amsacrine SCHEMBL29350869 | 1.00 | TOP2B (1.00) | TOP2BTOP2AKDM1ACYP1A2CYP2D6 | |
| Amsacrine SCHEMBL28336991 | 1.00 | TOP2B (1.00) | TOP2BTOP2AKDM1ACYP1A2CYP2D6 | |
| Amsacrine SCHEMBL6256280 | 1.00 | TOP2B (1.00) | TOP2BTOP2AKDM1ACYP1A2CYP2D6 | |
| Amsacrine SCHEMBL31316257 | 0.99 | KMT2A (1.00) | TOP2BTOP2AKDM1ACYP1A2CYP2D6 | |
| Amsacrine SCHEMBL1320825 | 0.99 | KMT2A (1.00) | TOP2BTOP2AKDM1ACYP1A2CYP2D6 | |
| Amsacrine SCHEMBL31237896 | 0.98 | TOP2B (0.95) | TOP2BTOP2AKDM1ACYP1A2CYP2D6 | |
| Amsacrine SCHEMBL2920983 | 0.98 | TOP2B (0.95) | TOP2BTOP2AKDM1ACYP1A2CYP2D6 | |
| Amsacrine SCHEMBL21827756 | 0.94 | TOP2B (0.89) | TOP2BTOP2AKDM1ACYP1A2CYP2D6 | |
| SCHEMBL9739742 | 0.94 | TOP2B (0.88) | TOP2BTOP2AKDM1ACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 84173 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122075497-A | Use of NLRP3 agonist for tumor treatment | — | 2026-05-26 | — | — | CN | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| US-20260137806-A1 | INTERCALATING SUGAR MOLECULES | XALUD THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| WO-2026102332-A1 | NERVE AND TUMOR HOMING AGENTS AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2026-05-15 | — | — | WO | claimed |
| WO-2025136820-A9 | POLY-ANTIGEN CYTOKINE-RECEPTOR COMPLEXES (PACCS), COMPOSITIONS, AND METHODS OF USE | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2026-05-15 | — | — | WO | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| EP-0359347-A2 | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging | NEORX CORPORATION (US) | 1990-03-21 | — | — | EP | claimed |
| EP-0335545-A2 | Pharmaceutical formulations for parenteral use | UNIVERSITY OF FLORIDA (US) | 1989-10-04 | — | — | EP | claimed |
| US-4704397-A | ANTITUMOR AGENTS | WARNER-LAMBERT COMPANY (US) | 1987-11-03 | — | — | US | claimed |
| EP-0042553-B1 | ANTITUMOR COMPOSITIONS | Bristol-Myers Company (US) | 1985-09-18 | — | — | EP | claimed |
| EP-0120907-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | Aston Molecules Limited (GB) | 1984-10-10 | — | — | EP | claimed |
| US-4472582-A | 3,5-Disubstituted-4'-(9-acridinylamino)-methane-sulfon-m-anisidide compounds having antitumor properties | DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND (NZ) | 1984-09-18 | — | — | US | claimed |
| EP-0035862-B1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 4'-(9-ACRIDINYLAMINO) METHANESULFON-M-ANISIDIDE, THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH SALTS | WARNER-LAMBERT COMPANY (US) | 1984-06-13 | — | — | EP | claimed |
| WO-1984001506-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | UNIV BIRMINGHAM (GB) | 1984-04-26 | — | — | WO | claimed |
| EP-0035862-A2 | Pharmaceutically acceptable salts of 4'-(9-acridinylamino) methanesulfon-m-anisidide, their production, and pharmaceutical compositions containing such salts | WARNER-LAMBERT COMPANY (US) | 1981-09-16 | — | — | EP | claimed |